NCT03990454View on ClinicalTrials.gov

Safety Study of SLC-391 in Subjects With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

September 17, 2019

Primary Completion Date

June 30, 2023

Study Completion Date

June 30, 2023

Conditions
Solid Tumor
Interventions
DRUG

SLC-391

SLC-391 is an AXL inhibitor

Trial Locations (3)

L8V 5C2

Juravinski Cancer Centre, Hamilton

K1H 8L6

The Ottawa Hospital Cancer Center, Ottawa

M5G 2M9

Princess Margaret Cancer Centre, Toronto

All Listed Sponsors
lead

SignalChem Lifesciences Corporation

INDUSTRY

NCT03990454 - Safety Study of SLC-391 in Subjects With Solid Tumors | Biotech Hunter | Biotech Hunter